TY - JOUR
T1 - Sugammadex
T2 - What do we know and what do we still need to know? A review of the recent (2013 to 2014) literature
AU - Ledowski, T.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Since its launch in 2008, sugammadex has been considered one of the most significant developments in anaesthesia-related pharmacology. With almost 500 sugammadex-related publications and over nine million patient exposures worldwide, user experience and scientific data have grown exponentially. However, several important questions are yet to be answered. This article reviews the sugammadex-related literature in 2013 and 2014 to determine which of these questions have been answered more fully over the last 18 months and which questions require more information and research.
AB - Since its launch in 2008, sugammadex has been considered one of the most significant developments in anaesthesia-related pharmacology. With almost 500 sugammadex-related publications and over nine million patient exposures worldwide, user experience and scientific data have grown exponentially. However, several important questions are yet to be answered. This article reviews the sugammadex-related literature in 2013 and 2014 to determine which of these questions have been answered more fully over the last 18 months and which questions require more information and research.
KW - Residual neuromuscular blockade
KW - Sugammadex
UR - http://www.scopus.com/inward/record.url?scp=84920446918&partnerID=8YFLogxK
U2 - 10.1177/0310057X1504300104
DO - 10.1177/0310057X1504300104
M3 - Article
C2 - 25579285
AN - SCOPUS:84920446918
SN - 0310-057X
VL - 43
SP - 14
EP - 22
JO - Anaesthesia and Intensive Care
JF - Anaesthesia and Intensive Care
IS - 1
ER -